Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease

Rachel F. Buckley; Paul Maruff; David Ames; Pierrick Bourgeat; Ralph N. Martins; Colin L. Masters; Stephanie Rainey-Smith; Nicola Lautenschlager; Christopher C. Rowe; Greg Savage; Victor L. Villemagne; Kathryn A. Ellis

doi:10.1016/j.jalz.2015.12.013

Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease

Rachel F. Buckley^*, Paul Maruff, David Ames, Pierrick Bourgeat, Ralph N. Martins, Colin L. Masters, Stephanie Rainey-Smith, Nicola Lautenschlager, Christopher C. Rowe, Greg Savage, Victor L. Villemagne, Kathryn A. Ellis

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

70 Citations (Scopus)

Abstract

Introduction The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). Methods Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. Results In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4–20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. Discussion High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.

Original language	English
Pages (from-to)	796-804
Number of pages	9
Journal	Alzheimer's and Dementia
Volume	12
Issue number	7
DOIs	https://doi.org/10.1016/j.jalz.2015.12.013
Publication status	Published - 1 Jul 2016

Keywords

Amyloid
PET imaging
Preclinical AD
Prodromal AD
Subjective cognitive decline
Subjective memory decline cognitively normal older adults

Access to Document

10.1016/j.jalz.2015.12.013

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease'. Together they form a unique fingerprint.

Cite this

Buckley, R. F., Maruff, P., Ames, D., Bourgeat, P., Martins, R. N., Masters, C. L., Rainey-Smith, S., Lautenschlager, N., Rowe, C. C., Savage, G., Villemagne, V. L., & Ellis, K. A. (2016). Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimer's and Dementia, 12(7), 796-804. https://doi.org/10.1016/j.jalz.2015.12.013

Buckley, Rachel F. ; Maruff, Paul ; Ames, David ; Bourgeat, Pierrick ; Martins, Ralph N. ; Masters, Colin L. ; Rainey-Smith, Stephanie ; Lautenschlager, Nicola ; Rowe, Christopher C. ; Savage, Greg ; Villemagne, Victor L. ; Ellis, Kathryn A. / Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. In: Alzheimer's and Dementia. 2016 ; Vol. 12, No. 7. pp. 796-804.

@article{feae999933de424dbf9826098e155556,

title = "Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease",

abstract = "Introduction The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). Methods Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. Results In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4–20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. Discussion High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.",

keywords = "Amyloid, PET imaging, Preclinical AD, Prodromal AD, Subjective cognitive decline, Subjective memory decline cognitively normal older adults",

author = "Buckley, {Rachel F.} and Paul Maruff and David Ames and Pierrick Bourgeat and Martins, {Ralph N.} and Masters, {Colin L.} and Stephanie Rainey-Smith and Nicola Lautenschlager and Rowe, {Christopher C.} and Greg Savage and Villemagne, {Victor L.} and Ellis, {Kathryn A.}",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.jalz.2015.12.013",

language = "English",

volume = "12",

pages = "796--804",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Wiley-Blackwell, Wiley",

number = "7",

}

Buckley, RF, Maruff, P, Ames, D, Bourgeat, P, Martins, RN, Masters, CL, Rainey-Smith, S, Lautenschlager, N, Rowe, CC, Savage, G, Villemagne, VL & Ellis, KA 2016, 'Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease', Alzheimer's and Dementia, vol. 12, no. 7, pp. 796-804. https://doi.org/10.1016/j.jalz.2015.12.013

Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. / Buckley, Rachel F.; Maruff, Paul; Ames, David; Bourgeat, Pierrick; Martins, Ralph N.; Masters, Colin L.; Rainey-Smith, Stephanie; Lautenschlager, Nicola; Rowe, Christopher C.; Savage, Greg; Villemagne, Victor L.; Ellis, Kathryn A.

In: Alzheimer's and Dementia, Vol. 12, No. 7, 01.07.2016, p. 796-804.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease

AU - Buckley, Rachel F.

AU - Maruff, Paul

AU - Ames, David

AU - Bourgeat, Pierrick

AU - Martins, Ralph N.

AU - Masters, Colin L.

AU - Rainey-Smith, Stephanie

AU - Lautenschlager, Nicola

AU - Rowe, Christopher C.

AU - Savage, Greg

AU - Villemagne, Victor L.

AU - Ellis, Kathryn A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Introduction The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). Methods Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. Results In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4–20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. Discussion High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.

AB - Introduction The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). Methods Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. Results In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4–20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. Discussion High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.

KW - Amyloid

KW - PET imaging

KW - Preclinical AD

KW - Prodromal AD

KW - Subjective cognitive decline

KW - Subjective memory decline cognitively normal older adults

UR - http://www.scopus.com/inward/record.url?scp=84959212040&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2015.12.013

DO - 10.1016/j.jalz.2015.12.013

M3 - Article

C2 - 26852195

AN - SCOPUS:84959212040

VL - 12

SP - 796

EP - 804

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 7

ER -